Optibumin® X
High-purity, 25% recombinant human serum albumin with an ultra-low fatty acid profile for stem cell (iPSC/MSC/etc.) and lipid-sensitive applications, supplied in saline with no added stabilizers.
Performance. Defined.
Recombinant Albumin
Cellastim® S, Optibumin® 25, Optibumin® 20, Optibumin® X, and Exbumin® replace bovine serum albumin and plasma-derived HSA across media supplementation, cell-therapy cryopreservation, drug conjugation, and injectable formulation.
overview
Albumin is the most abundant protein component of mammalian blood serum. It binds and transports ions, fatty acids, vitamins, hormones, small-molecule drugs, and toxins, regulates serum pH and osmotic pressure, and contributes antioxidant activity. Historically the most abundant laboratory-grade source has been bovine serum, BSA or FBS, which carries TSE/BSE risk, undefined contaminating protein content, as well as herd and seasonal variability. Plasma-derived HSA carries donor-pool variability, adventitious viral, prion, and bacterial pathogen risk, and the stabilizers pasteurization requires.
InVitria expresses all albumin products on ExpressTec™, a non-mammalian, rice-based expression platform, at an ISO 9001:2015-certified, cGMP-compliant facility in Junction City, Kansas. Raw materials, production host, manufacturing equipment, and product-contact packaging are all animal-free.




High-purity, 25% recombinant human serum albumin with an ultra-low fatty acid profile for stem cell (iPSC/MSC/etc.) and lipid-sensitive applications, supplied in saline with no added stabilizers.
Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.
Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.
High-purity recombinant human serum albumin excipient, a 20% w/v liquid for cell processing, cryopreservation, and final formulation.
Cell culture recombinant albumin to enhance proliferation in serum free and chemically defined cell culture. Lyophilized.
| Concentration | Lyophilized powder, reconstitute to 10 to 20% w/v | 25% w/v sterile liquid | 20% w/v sterile liquid | Lyophilized powder, reconstitute to 10 to 20% w/v | 25% w/v sterile liquid |
|---|---|---|---|---|---|
| Format | 10 g, 100 g + scale | 100 mL closed-system bag, 100 mL bottle + scale | 100 mL and 1 L bottles | 10 g, 100 g + scale | 100 mL bottle + scale |
| Best for | Serum-free cell culture media supplementation | Injectable final-formulation excipient. Closed-system applications; 25% drop-in for plasma HSA | Injectable final-formulation excipient. 20% drop-in for plasma HSA | Injectable excipient rHSA for final formulation where lyophilized powder is preferred. | Stem cell culture (iPSC/MSC/etc), lipid sensitive cell types, In Vitro Fertilization (IVF) |
| Grade | GMP | GMP, Excipient | GMP, Excipient | GMP, Excipient | GMP |
| Explore Cellastim S | Explore Optibumin 25 | Explore Optibumin 20 | Explore Exbumin | Explore Optibumin X |
Recombinant human serum albumin is produced using recombinant DNA technology in non-mammalian expression systems. It carries the same amino acid sequence as native human albumin, which gives human-sequence compatibility while removing animal-derived contamination risk. InVitria produces its rHSA on ExpressTec™, a non-mammalian, non-bacterial, and non-yeast production platform.
Yes. rHSA can directly replace BSA in upstream and downstream applications. It gives human-sequence compatibility, removes BSE contamination risk, delivers consistent lot-to-lot performance from a controlled expression process rather than a variable herd, and is suitable for GMP manufacturing environments.
Please see the comparison table above to help select the right rHSA for your needs. You may also reach out to the Product Applications Team for further information.
InVitria rHSA removes donor-to-donor variability, gives consistent lot-to-lot performance, and removes viral contamination risk, because it is not purified from pooled human plasma. It is animal-origin-free through raw materials, production host, manufacturing equipment, and product-contact packaging, and is covered by a published Certificate of Origin and Animal-Free / TSE-BSE Statement. That simplifies raw material risk assessment, supplier qualification, and comparability planning.
Yes. All five InVitria rHSA products are manufactured under a cGMP-compliant quality management system at the ISO 9001:2015-certified facility in Junction City, Kansas, and a lot-specific Certificate of Analysis is issued for every lot. For Cellastim® S, Optibumin® 20, Optibumin® 25, Optibumin® X, and Exbumin®, that quality management system is cGMP-compliant with respect to 21 CFR Part 210/211, and a product-specific Technical Summary carries CMC-style documentation: manufacturing process, raw material controls, characterization data, release specifications, and lot analysis. It supports IND, BLA, and comparable FDA and EMA filings, and goes directly to the customer rather than being filed as a Drug Master File.
Talk to the ProApps team
Format, grade, and concentration, the scale you run at, and the regulatory file your program has to support.